Literature DB >> 17425679

Aldo-keto reductase family 1, member B10 in uterine carcinomas: a potential risk factor of recurrence after surgical therapy in cervical cancer.

H Yoshitake1, M Takahashi, H Ishikawa, M Nojima, H Iwanari, A Watanabe, H Aburatani, K Yoshida, K Ishi, K Takamori, H Ogawa, T Hamakubo, T Kodama, Y Araki.   

Abstract

Aldo-keto reductase family 1, member B10 (AKR1B10), an enzyme that converts retinals into retinols is known to detect in non-small cell lung carcinoma (squamous cell- and adeno-carcinomas), but is barely expressed in normal tissues. Since these types of carcinoma occur frequently in the uterus (like in the lung), AKR1B10 may also be overexpressed in two major types of uterine cancer, cervical cancer (CC), and endometrial cancer (EMC). The objective of this study is to investigate AKR1B10 expression in uterine cancer and to analyze its clinical significance. In samples from uterine cancer patients, AKR1B10 was detected in 6 out of 30 (20.0%) CC cases and 6 out of 38 (15.8%) EMC cases. Statistical analysis indicated that AKR1B10 expression was associated with tumor recurrence after surgery and keratinization of squamous cell carcinoma only in CC. Although retinol (a metabolic product by AKR1B10) was observed in the normal epithelium, the molecule was not observed in cancer cells of AKR1B10-positive CC samples suggesting that the recurrence in CC may not depend on the convert of retinals into retinols via AKR1B10, a potential indicator in the management of patients with CC.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17425679     DOI: 10.1111/j.1525-1438.2007.00932.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  26 in total

1.  Functional expression of novel human and murine AKR1B genes.

Authors:  Joshua K Salabei; Xiao-Ping Li; J Mark Petrash; Aruni Bhatnagar; Oleg A Barski
Journal:  Chem Biol Interact       Date:  2011-01-27       Impact factor: 5.192

Review 2.  The aldo-keto reductase superfamily and its role in drug metabolism and detoxification.

Authors:  Oleg A Barski; Srinivas M Tipparaju; Aruni Bhatnagar
Journal:  Drug Metab Rev       Date:  2008       Impact factor: 4.518

3.  Aldoketoreductase family 1B10 (AKR1B10) as a biomarker to distinguish hepatocellular carcinoma from benign liver lesions.

Authors:  Kristina A Matkowskyj; Han Bai; Jie Liao; Wanying Zhang; Haonan Li; Sambasiva Rao; Reed Omary; Guang-Yu Yang
Journal:  Hum Pathol       Date:  2013-12-18       Impact factor: 3.466

Review 4.  Targeting aldose reductase for the treatment of cancer.

Authors:  Ravinder Tammali; Satish K Srivastava; Kota V Ramana
Journal:  Curr Cancer Drug Targets       Date:  2011-06       Impact factor: 3.428

5.  Compensatory upregulation of aldo-keto reductase 1B10 to protect hepatocytes against oxidative stress during hepatocarcinogenesis.

Authors:  Yongzhen Liu; Jing Zhang; Hui Liu; Guiwen Guan; Ting Zhang; Leijie Wang; Xuewei Qi; Huiling Zheng; Chia-Chen Chen; Jia Liu; Deliang Cao; Fengmin Lu; Xiangmei Chen
Journal:  Am J Cancer Res       Date:  2019-12-01       Impact factor: 6.166

6.  Carboplatin-gemcitabine combination chemotherapy upregulates AKR1B10 expression in bladder cancer.

Authors:  Yasuhiro Hashimoto; Kengo Imanishi; Noriko Tokui; Teppei Okamoto; Akiko Okamoto; Shingo Hatakeyama; Takahiro Yoneyama; Takuya Koie; Noritaka Kamimura; Chikara Ohyama
Journal:  Int J Clin Oncol       Date:  2011-12-27       Impact factor: 3.402

7.  Heat shock protein 90-α mediates aldo-keto reductase 1B10 (AKR1B10) protein secretion through secretory lysosomes.

Authors:  Dixian Luo; Yiwen Bu; Jun Ma; Sandeep Rajput; Yingchun He; Guangxian Cai; Duan-Fang Liao; Deliang Cao
Journal:  J Biol Chem       Date:  2013-11-11       Impact factor: 5.157

Review 8.  Fibrates in the chemical action of daunorubicin.

Authors:  Ganesaratnam K Balendiran
Journal:  Curr Cancer Drug Targets       Date:  2009-05       Impact factor: 3.428

9.  Aldo-keto reductase family 1 member B10 promotes cell survival by regulating lipid synthesis and eliminating carbonyls.

Authors:  Chun Wang; Ruilan Yan; Dixian Luo; Kounosuke Watabe; Duan-Fang Liao; Deliang Cao
Journal:  J Biol Chem       Date:  2009-07-30       Impact factor: 5.157

10.  Inhibiting wild-type and C299S mutant AKR1B10; a homologue of aldose reductase upregulated in cancers.

Authors:  Malkhey Verma; Hans-Joerg Martin; Wahajul Haq; Timothy R O'Connor; Edmund Maser; Ganesaratnam K Balendiran
Journal:  Eur J Pharmacol       Date:  2008-02-05       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.